AROMA-BIT
23.7.2019 03:32:07 CEST | Business Wire | Press release
Aroma Bit launched a new subsidiary to develop the next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact, high resolution and low cost. The technology is realized by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology and associated companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005004/en/
Aroma Bit: http://www.aromabit.com
Realizing smartphone embeddable smell sensor with dog nose equivalent ultra-high resolution smell sensor on only 1 millimeter square silicon die size
Aroma Bit has developed and are currently selling a compact smell sensor that employs QCM or Quartz Crystal Microbalance type sensor substrate, which demonstrates ultra-high sensitivity in the sensor market. However, further size reduction, cost reduction to meet high volume application market, such as smartphone, was challenging with conventional QCM type smell sensor.
With the newly developed silicon CMOS type smell sensor, ultra-compact, high smell resolution and low cost can be realized, to be embedded to system such as smartphone or IoT devices. For instance, it is expected that resolution equivalent to dog nose’s resolution (roughly 1,200 receptors) within 1mm die size can be achieved using the new type of sensor substrate.
With new addition of sensor substrate technology, Aroma Bit now holds two types of sensor substrate technology line up: (1) conventional and yet ultra-high sensitivity QCM type sensor substrate technology, and (2) ultra-high resolution, ultra-compact, low cost silicon CMOS type sensor substrate technology. Combined, highly competitive sensor technology portfolio is realized in two key performance for smell sensor, namely, sensor sensitivity and smell resolution. As a result, the addition of the new sensor is expected to further enhances Aroma Bit’s technology competitive advantage against its competitors in the compact smell sensor space.
Aroma Bit is currently also accelerating its development of digital smell database or smell big-data based on its hardware competitive advantage. Sensor hardware and smell database together, Aroma Bit is committed to retain its top-position in growing digital olfactory market, thereby realizing Aroma Bit’s vision “to realize a better world by visualizing the world of smell/aroma through odor imaging technology.”
New subsidiary certified as the first Toyohashi University of Technology University- Launched Venture Company
The new developed subsidiary, Aroma Bit Silicon Sensor Technology, Inc., is certified as the first Toyohashi University of Technology certified University-Launch Venture Company.
While University-Launched Venture company is on the rise in Japan, there is limited successful case leading to industrialization, due to factors such as lack of intellectual property conflict among large companies interest, skill set mismatch on researcher as entrepreneurs, among others.
In this particular Industry-academia collaboration case, the chance to commercialize technology is expected to increase by assigning venture company a role to drive business development of the technology developed jointly with university.
Background:
Aroma Bit succeeded in developing next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact and high resolution by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology.
In 2017, Toyohashi Technology of University, Toyohashi Sensor Kyogikai Corporation, Hamamatsu Photonics K.K., Toho Technology Corporation, Nippon Chemi-con Corporation and Aroma Bit together formed private Consortium COSCo (CMOS Odor Sensor Consortium). In 2018, COSCo consortium released working prototypes such as Kaori-Camera (Aroma Camera) and i-sniffer.
In the interest to aggregate the achievement from COSCo consortium and further accelerate development and industrialization, Aroma Bit Silicon Sensor Technology, Inc. (Hereafter, “ABSST”) is founded as Aroma Bit’s subsidiary.
Going forward, ABSST is committed to develop the silicon CMOS type next generation smell sensor that are ultra-high resolution, ultra-compact and low-cost embeddable to smartphone and IoT Devices.
New Subsidiary Company Profile |
|
Name of company: |
Aroma Bit Silicon Sensor Technology Inc. (ABSST) |
Date of Registration: |
June 28th, 2019 |
Paid-in-Capital: |
10 Million JPY [Aroma Bit, Inc. Subsidiary] |
Business Profile: |
Planning, Development, Manufacturing and Sales of silicon CMOS based next generation smell, gas sensor, and other related business |
Representative Management: |
Representative Director & CEO Shunichiro Kuroki [Current Representative Director & CEO of Aroma Bit, Inc.] |
Address: |
E205 KSP 3-2-1 Sakado, Takatsu-ku, Kawasaki-city, Kanagawa 213-0012 [Aroma Bit Kawasaki Lab] |
Corporate URL: |
|
Contact: |
Email: info@aromabitsst.com
|
About Aroma Bit |
Aroma Bit develops, produces and sells electronic equipments and systems including compact odor imaging sensors. |
[Corporate summary] |
|
Name: |
Aroma Bit, Inc. |
Address: |
Sagami Building 2F 7-13-6 Ginza, Chuo-ku, Tokyo |
Representative: |
Representative Director & CEO Sunichiro Kuroki |
Established: |
February, 2014 |
Business: |
- Development, Production and Sales of electronic equipments and systems including compact odor imaging sensors. |
- Development, Production and Sales of innovative services using the Sensor products. |
|
|
- Other business related to the above. |
Corporate URL: |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20190722005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
